カテゴリー： Market Monitor Global, 世界, 医療/バイオ

筋層非浸潤性膀胱癌治療の世界市場見通し2023年-2029年

◆英語タイトル：Non-Muscle-Invasive Bladder Cancer Treatment Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23JU5386）

◆商品コード：MMG23JU5386
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年6月
◆ページ数：63
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医療機器＆消耗品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥487,500	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥633,750	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥731,250	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Non-Muscle-Invasive Bladder Cancer Treatment Market 調査レポートは次の情報を含め、グローバルにおけるの筋層非浸潤性膀胱癌治療市場規模と予測を収録しています。・世界の筋層非浸潤性膀胱癌治療市場：売上、2018年-2023年、2024年-2029年
・世界の筋層非浸潤性膀胱癌治療市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の筋層非浸潤性膀胱癌治療市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「低リスク性筋層非浸潤性膀胱癌治療」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

筋層非浸潤性膀胱癌治療のグローバル主要企業は、Ferring Pharmaceuticals、 Merck、 Sesen Bio、 CG Oncology、 ImmunityBio、 Theralase、 Viventia Bio Inc.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、筋層非浸潤性膀胱癌治療のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の筋層非浸潤性膀胱癌治療市場：タイプ別、2018年-2023年、2024年-2029年
世界の筋層非浸潤性膀胱癌治療市場：タイプ別市場シェア、2022年
・低リスク性筋層非浸潤性膀胱癌治療、中リスク性筋層非浸潤性膀胱癌治療、高リスク性筋層非浸潤性膀胱癌治療

世界の筋層非浸潤性膀胱癌治療市場：用途別、2018年-2023年、2024年-2029年
世界の筋層非浸潤性膀胱癌治療市場：用途別市場シェア、2022年
・病院、診療所、その他

世界の筋層非浸潤性膀胱癌治療市場：地域・国別、2018年-2023年、2024年-2029年
世界の筋層非浸潤性膀胱癌治療市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における筋層非浸潤性膀胱癌治療のグローバル売上、2018年-2023年
・主要企業における筋層非浸潤性膀胱癌治療のグローバル売上シェア、2022年
・主要企業における筋層非浸潤性膀胱癌治療のグローバル販売量、2018年-2023年
・主要企業における筋層非浸潤性膀胱癌治療のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Ferring Pharmaceuticals、 Merck、 Sesen Bio、 CG Oncology、 ImmunityBio、 Theralase、 Viventia Bio Inc.

*************************************************************

・調査・分析レポートの概要
筋層非浸潤性膀胱癌治療市場の定義
市場セグメント
世界の筋層非浸潤性膀胱癌治療市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の筋層非浸潤性膀胱癌治療市場規模
世界の筋層非浸潤性膀胱癌治療市場規模：2022年 VS 2029年
世界の筋層非浸潤性膀胱癌治療市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの筋層非浸潤性膀胱癌治療の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の筋層非浸潤性膀胱癌治療製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：低リスク性筋層非浸潤性膀胱癌治療、中リスク性筋層非浸潤性膀胱癌治療、高リスク性筋層非浸潤性膀胱癌治療
筋層非浸潤性膀胱癌治療のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、その他
筋層非浸潤性膀胱癌治療の用途別グローバル売上・予測

・地域別市場分析
地域別筋層非浸潤性膀胱癌治療市場規模 2022年と2029年
地域別筋層非浸潤性膀胱癌治療売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Ferring Pharmaceuticals、 Merck、 Sesen Bio、 CG Oncology、 ImmunityBio、 Theralase、 Viventia Bio Inc.
...

This report aims to provide a comprehensive presentation of the global market for Non-Muscle-Invasive Bladder Cancer Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Muscle-Invasive Bladder Cancer Treatment. This report contains market size and forecasts of Non-Muscle-Invasive Bladder Cancer Treatment in global, including the following market information:
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Non-Muscle-Invasive Bladder Cancer Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-Muscle-Invasive Bladder Cancer Treatment include Ferring Pharmaceuticals, Merck, Sesen Bio, CG Oncology, ImmunityBio, Theralase and Viventia Bio Inc., etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-Muscle-Invasive Bladder Cancer Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Muscle-Invasive Bladder Cancer Treatment Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, by Type, 2022 (%)
Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
Global Non-Muscle-Invasive Bladder Cancer Treatment Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Non-Muscle-Invasive Bladder Cancer Treatment Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Non-Muscle-Invasive Bladder Cancer Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Muscle-Invasive Bladder Cancer Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Muscle-Invasive Bladder Cancer Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Ferring Pharmaceuticals
Merck
Sesen Bio
CG Oncology
ImmunityBio
Theralase
Viventia Bio Inc.
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Muscle-Invasive Bladder Cancer Treatment, market overview.
Chapter 2: Global Non-Muscle-Invasive Bladder Cancer Treatment market size in revenue.
Chapter 3: Detailed analysis of Non-Muscle-Invasive Bladder Cancer Treatment company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Muscle-Invasive Bladder Cancer Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Non-Muscle-Invasive Bladder Cancer Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-Muscle-Invasive Bladder Cancer Treatment Overall Market Size
2.1 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size: 2022 VS 2029
2.2 Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market
3.2 Top Global Non-Muscle-Invasive Bladder Cancer Treatment Companies Ranked by Revenue
3.3 Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue by Companies
3.4 Top 3 and Top 5 Non-Muscle-Invasive Bladder Cancer Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-Muscle-Invasive Bladder Cancer Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market
3.6.1 List of Global Tier 1 Non-Muscle-Invasive Bladder Cancer Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size Markets, 2022 & 2029
4.1.2 Low-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.1.3 Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.1.4 High-Risk Non-Muscle-Invasive Bladder Cancer Treatment
4.2 By Type – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
4.2.1 By Type – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2023
4.2.2 By Type – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2024-2029
4.2.3 By Type – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2022 & 2029
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
5.2.1 By Application – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2023
5.2.2 By Application – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2024-2029
5.2.3 By Application – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2022 & 2029
6.2 By Region – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue & Forecasts
6.2.1 By Region – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2023
6.2.2 By Region – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2024-2029
6.2.3 By Region – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029
6.3.2 US Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.3.3 Canada Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.3.4 Mexico Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029
6.4.2 Germany Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.3 France Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.4 U.K. Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.5 Italy Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.6 Russia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.7 Nordic Countries Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.4.8 Benelux Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029
6.5.2 China Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.5.3 Japan Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.5.4 South Korea Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.5.5 Southeast Asia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.5.6 India Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029
6.6.2 Brazil Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.6.3 Argentina Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029
6.7.2 Turkey Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.7.3 Israel Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.7.4 Saudi Arabia Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
6.7.5 UAE Non-Muscle-Invasive Bladder Cancer Treatment Market Size, 2018-2029
7 Non-Muscle-Invasive Bladder Cancer Treatment Companies Profiles
7.1 Ferring Pharmaceuticals
7.1.1 Ferring Pharmaceuticals Company Summary
7.1.2 Ferring Pharmaceuticals Business Overview
7.1.3 Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.1.4 Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.1.5 Ferring Pharmaceuticals Key News & Latest Developments
7.2 Merck
7.2.1 Merck Company Summary
7.2.2 Merck Business Overview
7.2.3 Merck Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.2.4 Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.2.5 Merck Key News & Latest Developments
7.3 Sesen Bio
7.3.1 Sesen Bio Company Summary
7.3.2 Sesen Bio Business Overview
7.3.3 Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.3.4 Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.3.5 Sesen Bio Key News & Latest Developments
7.4 CG Oncology
7.4.1 CG Oncology Company Summary
7.4.2 CG Oncology Business Overview
7.4.3 CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.4.4 CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.4.5 CG Oncology Key News & Latest Developments
7.5 ImmunityBio
7.5.1 ImmunityBio Company Summary
7.5.2 ImmunityBio Business Overview
7.5.3 ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.5.4 ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.5.5 ImmunityBio Key News & Latest Developments
7.6 Theralase
7.6.1 Theralase Company Summary
7.6.2 Theralase Business Overview
7.6.3 Theralase Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.6.4 Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.6.5 Theralase Key News & Latest Developments
7.7 Viventia Bio Inc.
7.7.1 Viventia Bio Inc. Company Summary
7.7.2 Viventia Bio Inc. Business Overview
7.7.3 Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Major Product Offerings
7.7.4 Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global Market (2018-2023)
7.7.5 Viventia Bio Inc. Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Non-Muscle-Invasive Bladder Cancer Treatment Market Opportunities & Trends in Global Market
Table 2. Non-Muscle-Invasive Bladder Cancer Treatment Market Drivers in Global Market
Table 3. Non-Muscle-Invasive Bladder Cancer Treatment Market Restraints in Global Market
Table 4. Key Players of Non-Muscle-Invasive Bladder Cancer Treatment in Global Market
Table 5. Top Non-Muscle-Invasive Bladder Cancer Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Non-Muscle-Invasive Bladder Cancer Treatment Product Type
Table 9. List of Global Tier 1 Non-Muscle-Invasive Bladder Cancer Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Non-Muscle-Invasive Bladder Cancer Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Non-Muscle-Invasive Bladder Cancer Treatment Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2024-2029
Table 30. Ferring Pharmaceuticals Company Summary
Table 31. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 32. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 33. Ferring Pharmaceuticals Key News & Latest Developments
Table 34. Merck Company Summary
Table 35. Merck Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 36. Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 37. Merck Key News & Latest Developments
Table 38. Sesen Bio Company Summary
Table 39. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 40. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 41. Sesen Bio Key News & Latest Developments
Table 42. CG Oncology Company Summary
Table 43. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 44. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 45. CG Oncology Key News & Latest Developments
Table 46. ImmunityBio Company Summary
Table 47. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 48. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 49. ImmunityBio Key News & Latest Developments
Table 50. Theralase Company Summary
Table 51. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 52. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 53. Theralase Key News & Latest Developments
Table 54. Viventia Bio Inc. Company Summary
Table 55. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Product Offerings
Table 56. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue (US$, Mn) & (2018-2023)
Table 57. Viventia Bio Inc. Key News & Latest Developments
List of Figures
Figure 1. Non-Muscle-Invasive Bladder Cancer Treatment Segment by Type in 2022
Figure 2. Non-Muscle-Invasive Bladder Cancer Treatment Segment by Application in 2022
Figure 3. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Non-Muscle-Invasive Bladder Cancer Treatment Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Non-Muscle-Invasive Bladder Cancer Treatment Revenue in 2022
Figure 8. By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 9. By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 10. By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 12. By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 14. By Region - Global Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 15. By Country - North America Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 16. US Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 20. Germany Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 21. France Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 28. China Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 32. India Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 34. Brazil Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Non-Muscle-Invasive Bladder Cancer Treatment Revenue Market Share, 2018-2029
Figure 37. Turkey Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Non-Muscle-Invasive Bladder Cancer Treatment Revenue, (US$, Mn), 2018-2029
Figure 41. Ferring Pharmaceuticals Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Merck Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Sesen Bio Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. CG Oncology Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. ImmunityBio Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Theralase Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Viventia Bio Inc. Non-Muscle-Invasive Bladder Cancer Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 筋層非浸潤性膀胱癌治療の世界市場見通し2023年-2029年(Non-Muscle-Invasive Bladder Cancer Treatment Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

筋層非浸潤性膀胱癌治療の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp